Evidence map›Paper›PMID 39023561›Full record

ArticleNucleic acid therapeutics2024

mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs

Sarah Allen, Daniel O'Reilly, Rachael Miller, Ellen Sapp, Ashley Summers, Joseph Paquette, Dimas Echeverria Moreno, Brianna Bramato, Nicholas McHugh, Ken Yamada and 3 more

Abstract read
In one paragraph

Article in Nucleic acid therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Sarah AllenRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Daniel O'ReillyRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Rachael MillerRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Ellen SappDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Ashley SummersRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Joseph PaquetteRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Dimas Echeverria MorenoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Brianna BramatoRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Nicholas McHughRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Ken YamadaRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Neil AroninRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Marian DiFigliaDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Anastasia KhvorovaRNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.

Funding

Advancing RNA Therapeutics for Huntington’s DiseaseU01NS114098 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ARONIN, NEIL · 2020 to 2024
$6.7M
Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disordersR01NS104022 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2017 to 2026
$6.0M
Chemical engineering of therapeutic RNAs for extrahepatic deliveryR35GM131839 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2019 to 2026
$3.1M
Selective Editing of the Mutant Huntingtin GeneR01NS106245 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ARONIN, NEIL · 2018 to 2022
$2.4M
Mid-Scale RNA Synthesis, Purification and Quality Control SystemS10OD020012 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KHVOROVA, ANASTASIA · 2015 to 2015
$563k
Examining the Role of a Pathogenic HTT Isoform, HTT1a, in Somatic Expansion and RNA Aggregation in Huntington's DiseaseF31NS137681 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Sarah Jane Allen · 2024 to 2026
$103k
NIGMS NIH HHS R35 GM131839NIH HHS S10 OD020012NINDS NIH HHS F31 NS137681NINDS NIH HHS R01 NS104022NINDS NIH HHS R01 NS106245NINDS NIH HHS U01 NS114098
6 · The paper itself

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the first exon of the huntingtin gene (

Indexed as

Cell NucleusHuntingtin ProteinHuntington DiseaseRNA, MessengerRNA, Small InterferingAnimalsDisease Models, AnimalGene SilencingHumansMiceMutationHTT protein, humanHtt protein, mouseHuntingtin ProteinRNA, MessengerRNA, Small InterferingHuntington’s diseasemRNA aggregationnuclear localizationsiRNA

Identifiers

PMID39023561
PMCPMC11387003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.